LYRA

LYRA

USD

Lyra Therapeutics Inc. Common Stock

$12.830-0.500 (-3.751%)

Prix en Temps Réel

Healthcare
Biotechnologie
États-Unis

Graphique des Prix

Loading Chart...

Métriques Clés

Métriques de Marché
Fondamentaux de l'Entreprise
Statistiques de Trading

Métriques de Marché

Ouverture

$13.330

Haut

$13.502

Bas

$11.670

Volume

0.20M

Fondamentaux de l'Entreprise

Capitalisation Boursière

17.0M

Industrie

Biotechnologie

Pays

United States

Statistiques de Trading

Volume Moyen

0.65M

Bourse

NCM

Devise

USD

Intervalle sur 52 Semaines

Bas $3.81Actuel $12.830Haut $37.5

Actualités Connexes

Analyst Upgrades

HC Wainwright & Co. Maintains Neutral on Lyra Therapeutics, Raises Price Target to $16

HC Wainwright & Co. analyst Matthew Caufield maintains Lyra Therapeutics with a Neutral and raises the price target from $2 to $16.

Voir plus
HC Wainwright & Co. Maintains Neutral on Lyra Therapeutics, Raises Price Target to $16
GlobeNewswire

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078)ENLIGHTEN 2 trial also showed

Voir plus
Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS)

Restez Informé

Configurez des alertes de prix, recevez des mises à jour d'analyses IA et des actualités de marché en temps réel.